WeVote
Log In

Bill

Bill

SB 514

Chimeric antigen receptor T-cell therapy.

2025 Regular Session Introduced by Jean Leising

SB 514 establishes Indiana regulatory framework for CAR-T cell cancer immunotherapy, potentially affecting treatment access, insurance coverage, and patient eligibility.

First reading: referred to Committee on Health and Provider Services
#agencies;departmentofhealth(idoh) #agencies;familyandsocialservicesadministration(fssa) #healthcarefacilities;generally #insurance;healthinsurance #insurance;healthmaintenanceorganizations(hmos) #insurance;motorvehicles
0
WeVote Research Nonpartisan
Bill Summary · SB 514

Legislative bill overview

SB 514 appears to address regulatory or coverage frameworks for chimeric antigen receptor T-cell (CAR-T) therapy in Indiana. CAR-T therapy is an advanced immunotherapy that genetically modifies a patient's T cells to fight certain cancers. The bill's specific provisions are not yet publicly detailed given its early stage in the legislative process.

Why this is important

CAR-T therapies represent cutting-edge cancer treatment with FDA approval for multiple blood cancers, but they cost $373,000-$475,000 per treatment, creating significant access and insurance coverage challenges. Indiana legislation on this topic could affect patient eligibility, insurance requirements, and healthcare equity across the state.

Potential points of contention

  • Cost and insurance coverage: Whether insurers must cover CAR-T therapy and whether patients face prohibitive out-of-pocket costs
  • Provider qualifications: Requirements for hospitals and medical centers authorized to administer these complex therapies
  • Access equity: Whether the bill ensures equitable access across rural and underserved populations, or may inadvertently limit availability

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.